Next Meetings

May 23, 2019 9am- 5pm CT

Hyatt Regency O’Hare
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review evidence on esketamine as a therapy for treatment-resistant depression. The Council will also review a report on siponimod for treatment of secondary progressive MS during this meeting.

Register

Multiple Sclerosis

Midwest CEPAC
May 23, 2019 9am-5pm CT

Hyatt Regency O’Hare
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review ICER's assessment of siponimod (Novartis) for secondary progressive multiple sclerosis.

Register

June 11, 2019 10AM-4PM

California Endowment Oakland Conference Center
2000 Franklin St.
Oakland, CA 94612

CTAF will convene to review ICER's assessment of treatments for peanut allergy.

Register

Duchenne Muscular Dystrophy

New England CEPAC
July 25, 2019 10am-4pm ET

MIT Samberg Conference Center
50 Memorial Drive
Cambridge, MA 02142

The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for Duchenne muscular dystrophy.


Cardiovascular Disease

Midwest CEPAC
September 26, 2019 10am - 4pm CT

University of Missouri-St. Louis
Century BC Room, Millennium Student Center
1 University Boulevard
St. Louis, MO 63121

The Midwest CEPAC will convene to deliberate and vote on evidence presented in ICER's report on additive CVD therapies.


October 8, 2019

ICER will evaluate selected high-impact drugs with substantial price increases that occurred in the last quarter of 2018. ICER will review changes in the evidence base for each of these drugs and assess whether or not new clinical data exists that could suggest that the drugs could be significantly more beneficial for patients than what was previously understood. ICER will publish the final draft of its first UPI report in October 2019.


October 31, 2019 10am - 4pm PT

The California Endowment – Center for Healthy Communities Oakland
2000 Franklin Street
Oakland, CA 94612

CTAF will convene to review ICER's assessment of targeted immune modulators for rheumatoid arthritis.


Type 2 Diabetes

New England CEPAC
November 14, 2019 10am-4pm ET

TBD
Providence, RI

The New England CEPAC will convene to deliberate on ICER's review of oral semaglutide for the treatment of type 2 diabetes.


past Meetings

Sep 2018
Midwest CEPAC

Amyloidosis

The Midwest CEPAC deliberated and voted on ICER's report on treatments for hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. The Council also reviewd a report on therapies for prostate cancer during this meeting.